APPLICATION OF ASTRAGALOSIDE IN PREVENTING AND TREATING TYPE 2 DIABETIC NEPHROPATHY

摘要

An application of an astragaloside for preparing a pharmaceutical product for preventing and treating type 2 diabetic nephropathy. The astragaloside can reduce urine albumin excretion of a db/db mouse with type 2 diabetes, mitigate a pathological injury of a glomerulus and renal tubule, and reduce urine excretion of NAG, NGAL and TGF-β1. The astragaloside can also suppress an activation of an Akt/mTOR, NFκB, and Erk1/2 signal pathway, and does not exhibit significant hepatotoxicity.